Related Experiment Video For Ferroptosis
Updated: Jan 18, 2026
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Reprogramming cysteine metabolism via METTL14-SLC7A11 axis promotes the progression of NAFLD and hepatocellular
Xing He1, Yuqin Gu1, Guangyu Lu1
1The Sichuan Provincial Key Laboratory for Human Disease Gene Study and Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610072, China; Laboratory of Ageing Research, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610054, China; School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610054, China.
Abstract:
Non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC) constitute significant global health challenges, with their prevalence exacerbated by shifts in lifestyle and dietary habits. Cysteine metabolism is intricately linked to the synthesis of reductive glutathione (GSH) and the maintenance of redox homeostasis, both of which are essential for cellular viability. N6-methyladenosine (m6A) methylation has emerged as a critical regulatory mechanism influencing metabolic pathways and redox balance in the context of NAFLD and HCC. This study aimed to elucidate the role of METTL14 in cysteine metabolism and the progression of NAFLD and HCC in vivo by examining the amino acid metabolic profile of NAFLD-affected livers using a hepatocyte-specific METTL14 knockout mouse model. Our results demonstrate that deletion of METTL14 reduces m6A methylation of SLC7A11 mRNA, thereby impairing cystine uptake, disrupting cysteine-dependent GSH synthesis, and compromising mitochondrial structure and function. These alterations culminate in the accumulation of reactive oxygen species, enhanced lipid peroxidation, increased cell death, and the accelerated progression of NAFLD and diethylnitrosamine-induced HCC. Collectively, these findings suggest that targeting the METTL14-SLC7A11-cysteine-GSH axis may offer a novel therapeutic approach for mitigating the advancement of NAFLD and HCC.
More Related Videos
08:04Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
